Camrelizumab
Monoclonal antibody
Also known as SHR-1210
Evidence outlook
Approved: Recurrent or metastatic cervical cancer after platinum-based chemotherapy, without prior... (CN)
This approval is outside the US-scoped market view; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.
Also in development:Non-Small Cell Lung Cancer · Phase 3 · investigational in the USNasopharyngeal Carcinoma · Phase 3 · investigational in the USCervical Cancer · Phase 2/3 · investigational in the USGastric Cancer · Phase 3 · investigational in the US
Also approved (8)
- Recurrent or metastatic cervical cancer after platinum-based chemotherapy, without prior bevacizumab, with famitinib (conditional approval)
- First-line unresectable or metastatic hepatocellular carcinoma, with apatinib
- First-line locally advanced or metastatic squamous NSCLC, with carboplatin + paclitaxel
- First-line locally relapsed or metastatic nasopharyngeal carcinoma, with cisplatin + gemcitabine
- Advanced nasopharyngeal carcinoma progressed after or intolerable to second-line or later chemotherapy
- First-line unresectable locally advanced or metastatic EGFR-negative, ALK-negative non-squamous NSCLC, with pemetrexed + carboplatin
- Advanced hepatocellular carcinoma after sorafenib and/or oxaliplatin-containing chemotherapy
- Relapsed or refractory classic Hodgkin lymphoma after at least two systematic therapies (conditional approval; first approval)
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT03764293 NCT03764293 · Hepatocellular Carcinoma Registry: NCT03764293 | 3 | Overall Survival (OS) (Up to approximately 3 years); Progression-free Survival (PFS) Evaluated by the Blinded Independent Review Committee (BIRC) Based on RECIST v1.1 (Up to approximately 3 years) 2022-02-08 | Completed. Key figures are not recorded here. | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (45)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (13)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (331)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (40)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (28)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (1)
What this study did
Early phase / not applicable (33)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Used as active comparator (3)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 2/3 (3)
What this study did
What this study did
What this study did
Appears in other studies (16)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 3 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (8)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (1)
What this study did
Early phase / not applicable (2)
What this study did
What this study did
Competitive landscape
Other PD-1 drugs
Cemiplimab, Dostarlimab, Nivolumab, Opdivo Qvantig, Pembrolizumab and 21 more. Compare all 27 PD-1 drugs
This mechanism is crowded: 26 other tracked programmes target it, 10 of them ahead of this one.
This drug's own stage for Cervical Cancer: Phase 2/3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Camrelizumab: this drug | Phase 2/3 | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Alymsys (bevacizumab-Maly) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| BAT1706 (Avzivi) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Bevacizumab | Approved | Monoclonal antibody | VEGF-A, Vascular Endothelial Growth Factor Inhibitor | not yet graded | No reviewed efficacy summary in this indication | |
| Bevacizumab-Awwb (MVASI) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Jobevne (bevacizumab-Nwgd) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Pembrolizumab | Approved | Monoclonal antibody | PD-1 | Reliable signal | No reviewed efficacy summary in this indication | |
| Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex) | Approved | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Tisotumab Vedotin Humax-Tf-Adc (Tivdak) | Approved | Antibody–drug conjugate | Tissue Factor (TF) | Partial signal | NCT04697628: Overall Survival (From randomization to date of death due to any cause or censoring date, whichever occurred first (maximum up to 25 months)): Tisotumab Vedotin 11.5 Months (95% CI 9.8 to 14.9) | Chemotherapy 9.5 Months (95% CI 7.9 to 10.7) NCT03438396: Percentage of Participants With Confirmed Objective Response (OR) as Assessed by the Independent Review Committee (IRC) (From Day 1 through IRC verified disease progression, initiation of new anticancer therapy, study withdrawal, or death, whichever occurred first (approximately 20 months)): Tisotumab Vedotin 23.8 Percentage of Participants (95% CI 15.9 to 33.3) | |
| Vegzelma (bevacizumab-Adcd) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Zirabev (bevacizumab-Bvzr) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Cadonilimab | Phase 3 | Multispecific antibody | PD-1×CTLA-4 | not yet graded | No reviewed efficacy summary in this indication | |
| Enlonstobart | Phase 3 | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Famitinib | Phase 3 | Small molecule | c-Kit, VEGFR2 (KDR), PDGFRbeta, VEGFR3, FLT1, FLT3 | not yet graded | No reviewed efficacy summary in this indication | |
| Iparomlimab (QL1604) | Phase 3(overall) | Monoclonal antibody | PD-1 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Notiretatug Rezetecan | Phase 3 | Antibody–drug conjugate | Nectin-4 | not yet graded | No reviewed efficacy summary in this indication | |
| Sacituzumab Tirumotecan | Phase 3 | Antibody–drug conjugate | TROP2 | not yet graded | No reviewed efficacy summary in this indication | |
| Sutantatug Envedotin | Phase 3 | Antibody–drug conjugate | Nectin-4 | not yet graded | No reviewed efficacy summary in this indication | |
| Volrustomig | Phase 3 | Multispecific antibody | PD-1 x CTLA-4 | not yet graded | No reviewed efficacy summary in this indication | |
| Balstilimab | Phase 2 | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-3045 | Phase 2(overall) | Undisclosed | PD-1 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| ALE.P02 | Phase 1/2(overall) | Antibody–drug conjugate | Claudin-1 (CLDN1) | not yet graded | No reviewed efficacy summary in this indication | |
| GI-101A | Phase 1/2 | Protein / enzyme therapeutic | CTLA-4 / IL-2Rβγ | not yet graded | No reviewed efficacy summary in this indication | |
| Bmab1700 | Phase 1(overall) | Monoclonal antibody | PD-1 | not yet graded(overall) | No reviewed efficacy summary in this indication |
Compare side by side
17 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(81 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Camrelizumab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (15)
November 2026 (1)
What to watch
December 2026 (14)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
2027 (33)
January 2027 (2)
What to watch
What to watch
February 2027 (1)
What to watch
March 2027 (3)
What to watch
What to watch
What to watch
April 2027 (1)
What to watch
May 2027 (2)
June 2027 (1)
What to watch
July 2027 (1)
What to watch
August 2027 (2)
September 2027 (2)
October 2027 (1)
What to watch
November 2027 (2)
December 2027 (15)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
2028 (19)
January 2028 (2)
February 2028 (2)
March 2028 (2)
What to watch
What to watch
May 2028 (1)
What to watch
June 2028 (1)
What to watch
July 2028 (3)
What to watch
What to watch
What to watch
September 2028 (1)
What to watch
December 2028 (7)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
2029 (7)
January 2029 (2)
February 2029 (2)
What to watch
What to watch
October 2029 (1)
What to watch
2030 (3)
April 2030 (1)
What to watch
2031 (3)
March 2031 (1)
What to watch
April 2031 (1)
What to watch
December 2031 (1)
What to watch
2032 (1)
April 2032 (1)
What to watch
Regulatory and conference events
(3)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
Recent